Gram-negative pathogens (GNPs) are clinically important pathogens in both the hospital and outpatient settings. GNPs are often acquired in healthcare facilities, and therefore have a high incidence of drug resistance to even the most powerful of antibiotics. The rise in drug-resistance rates, including resistance to multiple classes of antibiotics, and the lack of newly approved agents in the last ten years has led to a critical need for new therapies for multi-drug-resistant (MDR) GNPs. This report provides insight into the management of patients with GN infections (GNIs) in the hospital setting and analyzes the hospital antibiotic prescribing practices for the treatment of key infections due to emerging and clinically important GNPs. The study provides longitudinal information on market dynamics, including insight into practice patterns, attitudes and perceptions, unmet needs, and projected use of antibiotics in the hospital setting. We also explore the physician-perceived advantages and disadvantages of emerging and currently available therapies, including two recently launched cephalosporin/beta-lactamase combinations—ceftolozane/tazobactam (Merck’s Zerbaxa) and ceftazidime/avibactam (Allergan/AstraZeneca’s Avycaz).